Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAIRO6: Perioperative systemic therapy plus CRS-HIPEC vs upfront CRS-HIPEC for resectable colorectal peritoneal metastases
2024-518570-13-00Phase 3Authorised
- Sponsor
- Catharina Ziekenhuis
- Start
- Nov 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of bevacizumab, capecitabine, fluorouracil, oxaliplatin, irinotecan and 1 more in colorectal cancer (CRC) (2 arms), sponsored by Catharina Ziekenhuis. Primary endpoint: overall survival. Planned start Nov 2024; status: authorised.
02
Drugs
bevacizumabcapecitabinefluorouraciloxaliplatinirinotecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2024-518570-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518570-13-00.